Roche’s Tecentriq (atezolizumab) Combination Therapy Receives Health Canada’s Approval for Metastatic Non-Squamous Non-Small Cell Lung Cancer in Adults

Roche’s Tecentriq (atezolizumab) + Abraxane Receive European Commission’s Approval for Patients with PD-L1-Positive Metastatic Triple-Negative Breast Cancer


  • The approval is based on P-III IMpower150 study results assessing Tecentriq + CT (carboplatin and paclitaxel) with/without Avastin (bevacizumab) vs Bevacizumab and CT in 1,202 patients in a ratio (1:1:1) with stage IV recurrent metastatic non-sq NSCLC, no prior treatment with CT
  • The P-III IMpower150 study results: OS (19.2 vs 14.7 mos.); no new safety signals are observed
  • Tecentriq is a mAb targeting PD-L1 expressing tumor cells when combined with bevacizumab + CT enhances its ability to restore anti-cancer immunity to combat 1L advanced NSCLC

Click here to read full press release/ article | Ref: PRNewswire | Image: Idworksglobal